Regenxbio (RGNX) Total Current Liabilities (2014 - 2025)

Regenxbio's Total Current Liabilities history runs 12 years deep, the most recent figure standing at $118.1 million for Q4 2025.

• In Q4 2025, Total Current Liabilities rose 14.44% year-over-year to $118.1 million; the TTM figure through Dec 2025 stood at $118.1 million (up 14.44% YoY), while the FY2025 annual figure was $118.1 million, up 14.44% from the prior year.
• Total Current Liabilities was $118.1 million for Q4 2025 at Regenxbio, down from $124.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $130.5 million in Q4 2021 to a low of $84.0 million in Q1 2021.
• Historically, Total Current Liabilities has averaged $113.6 million across 5 years, with a median of $116.2 million in 2022.
• The sharpest annual moves came in 2021 and 2024: Total Current Liabilities jumped 164.12% in 2021, then declined 20.79% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $130.5 million in 2021, then fell by 0.03% to $130.4 million in 2022, then decreased by 0.12% to $130.3 million in 2023, then dropped by 20.79% to $103.2 million in 2024, then advanced by 14.44% to $118.1 million in 2025.
• The last three Total Current Liabilities figures came in at $118.1 million (Q4 2025), $124.6 million (Q3 2025), and $119.5 million (Q2 2025), per Business Quant data.